Date:2/9/2010

n/a[3] Technical Plastics in % of sales 19.2 n/a[3] Profit from operations (EBIT) 60.4 61.0 -1.0 Net income 7.0 4.5 +55.6 Adjusted net income[4] 45.2 61.4 -26.4 Earnings per share in EUR 0.18 0.02 >+100 Adjusted earnings per share[5] in in EUR 1.34 1.83 -26.8 Equity ratio in % 35.8 31.6 Net financial debt 373.3 421.6 -11.5 Capital expenditure 86.4 107.8 -19.9 1 The Technical Plastic Systems segment was sold with effect from July 1, 2009 2 Adjusted EBITDA: Earnings before income taxes, financial result, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses 3 The adjusted EBITDA of the Technical Plastic Systems segment of the prior year is not available due to the fact that the divestment was carried out in the course of the financial year 2008 and is therefore included in the Plastic Systems segment 4 Adjusted net income: Consolidated profit before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, the balance of one-off income and expenses (including significant non-cash expenses) and the related tax effects 5 Adjusted net income after minorities divided by 31.4m shares Contact Press Burkhard Lingenberg Director Corporate Communication & Marketing Director Phone +49-211-6181-250 Fax +49-211-6181-241 e-mail b.lingenberg@gerresheimer.com Contact Investor Relations Anke Linnartz Corporate Investor Relations Phone +49-211-6181-314 Fax +49-211-6181-121 e-mail '/>"/>

SOURCE Gerresheimer AG Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Gerresheimer has Passed the Turning Point
2. Mirixa Australia Achieves Six Month Milestones
3. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
4. NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
5. EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
10. Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
11. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield